EA027501B1 - 5-алкинилпиримидины - Google Patents

5-алкинилпиримидины Download PDF

Info

Publication number
EA027501B1
EA027501B1 EA201201030A EA201201030A EA027501B1 EA 027501 B1 EA027501 B1 EA 027501B1 EA 201201030 A EA201201030 A EA 201201030A EA 201201030 A EA201201030 A EA 201201030A EA 027501 B1 EA027501 B1 EA 027501B1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
mmol
alkyl
independently
methoxy
Prior art date
Application number
EA201201030A
Other languages
English (en)
Russian (ru)
Other versions
EA201201030A1 (ru
Inventor
Зигфрид Шнайдер
Дирк Кесслер
Ларс Ван-дер-Вен
Тобиас Вунберг
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201030A1 publication Critical patent/EA201201030A1/ru
Publication of EA027501B1 publication Critical patent/EA027501B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Laminated Bodies (AREA)
  • Steroid Compounds (AREA)
EA201201030A 2010-01-26 2011-01-26 5-алкинилпиримидины EA027501B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151723 2010-01-26
PCT/EP2011/051061 WO2011092198A1 (en) 2010-01-26 2011-01-26 5-alkynyl-pyrimidines

Publications (2)

Publication Number Publication Date
EA201201030A1 EA201201030A1 (ru) 2013-02-28
EA027501B1 true EA027501B1 (ru) 2017-08-31

Family

ID=42224366

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201030A EA027501B1 (ru) 2010-01-26 2011-01-26 5-алкинилпиримидины

Country Status (39)

Country Link
US (3) US8633183B2 (enExample)
EP (1) EP2528903B1 (enExample)
JP (1) JP5746219B2 (enExample)
KR (1) KR101730933B1 (enExample)
CN (1) CN102781923B (enExample)
AP (1) AP3107A (enExample)
AR (1) AR080020A1 (enExample)
AU (1) AU2011209344B2 (enExample)
BR (1) BR112012019437A2 (enExample)
CA (1) CA2787407C (enExample)
CL (1) CL2012001821A1 (enExample)
CO (1) CO6640285A2 (enExample)
CY (1) CY1118129T1 (enExample)
DK (1) DK2528903T3 (enExample)
EA (1) EA027501B1 (enExample)
ES (1) ES2598230T3 (enExample)
GE (1) GEP20156229B (enExample)
HR (1) HRP20161308T1 (enExample)
HU (1) HUE030721T2 (enExample)
IL (1) IL220674A (enExample)
IN (1) IN2012DN06602A (enExample)
LT (1) LT2528903T (enExample)
MA (1) MA33939B1 (enExample)
ME (1) ME02511B (enExample)
MX (1) MX2012008128A (enExample)
MY (1) MY160241A (enExample)
NZ (1) NZ601121A (enExample)
PE (1) PE20121695A1 (enExample)
PH (1) PH12012501520A1 (enExample)
PL (1) PL2528903T3 (enExample)
PT (1) PT2528903T (enExample)
RS (1) RS55265B1 (enExample)
SG (1) SG182675A1 (enExample)
SI (1) SI2528903T1 (enExample)
TN (1) TN2012000369A1 (enExample)
TW (1) TWI596093B (enExample)
UA (1) UA110471C2 (enExample)
UY (1) UY33199A (enExample)
WO (1) WO2011092198A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590558A (en) 2008-07-29 2012-12-21 Boehringer Ingelheim Int 5-alkynyl-pyrimidines
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US8618111B2 (en) * 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
UY33199A (es) * 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
ES2573497T3 (es) 2011-02-02 2016-06-08 Vertex Pharmaceuticals Incorporated Pirrolopirazin-amidas de piperidina espirocíclicas como moduladores de canales iónicos
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
CA2829803A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) * 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
PL3196202T3 (pl) 2011-09-02 2019-09-30 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR092211A1 (es) * 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
ES2841137T3 (es) 2013-12-20 2021-07-07 Sagimet Biosciences Inc Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
ES2838573T3 (es) 2014-08-21 2021-07-02 Bristol Myers Squibb Co Derivados de benzamida ligados como inhibidores potentes de ROCK
MD3831833T2 (ro) 2015-02-27 2023-04-30 Incyte Holdings Corp Procedee pentru prepararea unui inhibitor PI3K
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
MX2023008968A (es) * 2021-01-29 2023-09-22 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.
US12053459B2 (en) 2021-06-26 2024-08-06 Cedilla Therapeutics, Inc. CDK2 inhibitors and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044823A2 (en) * 2004-10-18 2006-04-27 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006103449A2 (en) * 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
WO2008155140A1 (en) * 2007-06-20 2008-12-24 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as tie2 kinase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
EP0674627A1 (en) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5622954A (en) 1994-05-11 1997-04-22 Fmc Corporation 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
DE60142236D1 (de) 2000-07-24 2010-07-08 Krenitsky Pharmaceuticals Inc Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
CN100430389C (zh) * 2002-08-16 2008-11-05 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
US20060205740A1 (en) 2003-08-14 2006-09-14 Reno Michael J Chemical compounds
EP1737462B1 (en) 2003-12-24 2008-07-30 AstraZeneca AB Pyrimidines with tie2 (tek) activity
JP2006044823A (ja) * 2004-07-30 2006-02-16 Hitachi Building Systems Co Ltd 乗客コンベアのハンドレール案内装置
EP1807075A2 (en) * 2004-10-12 2007-07-18 Applied Research Systems ARS Holding N.V. Pi3 kinase gamma inhibitors for the treatment of anaemia
WO2006082373A1 (en) 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
US20080146599A1 (en) 2005-02-01 2008-06-19 Astrazeneca Ab Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
JP4993205B2 (ja) 2005-03-30 2012-08-08 塩野義製薬株式会社 チロシンキナーゼ阻害作用を有するピリミジン誘導体
GB0506467D0 (en) * 2005-03-31 2005-05-04 Astrazeneca Ab Compounds
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
US20090325957A1 (en) 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CN106045965A (zh) 2006-12-29 2016-10-26 爱尔兰詹森科学公司 抑制hiv的5,6‑取代的嘧啶类化合物
NZ590558A (en) * 2008-07-29 2012-12-21 Boehringer Ingelheim Int 5-alkynyl-pyrimidines
UY33199A (es) * 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8618111B2 (en) * 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044823A2 (en) * 2004-10-18 2006-04-27 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006103449A2 (en) * 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
WO2008155140A1 (en) * 2007-06-20 2008-12-24 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as tie2 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. A. MATULENKO ET AL.: "4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors.", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, no. 4, 15 February 2007 (2007-02-15), GB, pages 1586 - 1605, XP002585927, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.12.029 *

Also Published As

Publication number Publication date
US20140073621A1 (en) 2014-03-13
WO2011092198A1 (en) 2011-08-04
HK1175175A1 (zh) 2013-06-28
KR101730933B1 (ko) 2017-05-11
PH12012501520A1 (en) 2022-10-05
ES2598230T3 (es) 2017-01-26
PL2528903T3 (pl) 2017-01-31
IL220674A (en) 2017-08-31
ME02511B (me) 2017-02-20
TWI596093B (zh) 2017-08-21
TN2012000369A1 (en) 2014-01-30
AR080020A1 (es) 2012-03-07
JP2013518079A (ja) 2013-05-20
US20120028952A1 (en) 2012-02-02
IN2012DN06602A (enExample) 2015-10-23
AP2012006360A0 (en) 2012-08-31
CN102781923A (zh) 2012-11-14
PT2528903T (pt) 2016-10-25
CY1118129T1 (el) 2017-06-28
SG182675A1 (en) 2012-08-30
RS55265B1 (sr) 2017-02-28
CN102781923B (zh) 2016-03-02
CL2012001821A1 (es) 2012-11-30
KR20120118514A (ko) 2012-10-26
NZ601121A (en) 2014-07-25
US9321771B2 (en) 2016-04-26
CO6640285A2 (es) 2013-03-22
JP5746219B2 (ja) 2015-07-08
MX2012008128A (es) 2012-08-15
EP2528903A1 (en) 2012-12-05
PE20121695A1 (es) 2012-12-11
AU2011209344B2 (en) 2015-04-16
UY33199A (es) 2011-08-31
GEP20156229B (en) 2015-01-26
EA201201030A1 (ru) 2013-02-28
AP3107A (en) 2015-01-31
LT2528903T (lt) 2016-10-25
HRP20161308T1 (hr) 2016-12-02
US8633183B2 (en) 2014-01-21
TW201139408A (en) 2011-11-16
MY160241A (en) 2017-02-28
UA110471C2 (ru) 2016-01-12
SI2528903T1 (sl) 2016-11-30
MA33939B1 (fr) 2013-01-02
CA2787407C (en) 2015-11-24
EP2528903B1 (en) 2016-07-20
BR112012019437A2 (pt) 2018-03-20
HUE030721T2 (en) 2017-05-29
CA2787407A1 (en) 2011-08-04
AU2011209344A1 (en) 2012-08-02
US20160199383A1 (en) 2016-07-14
DK2528903T3 (en) 2016-11-14

Similar Documents

Publication Publication Date Title
EA027501B1 (ru) 5-алкинилпиримидины
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
JP2021522316A (ja) 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ−ｐｋ阻害剤
JP2020504139A (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
JP2013530953A (ja) 新規ｃｃｒ２アンタゴニスト
US9090564B2 (en) 5-alkynyl-pyridines
US20040127714A1 (en) Method of making tricyclic aminocyanopyridine compounds
WO2020257527A1 (en) Compounds for inhibiting fgfr4
EP2528910B1 (en) 5-Alkynyl pyrimidines ahd their use as kinase inhibitors.
CN120092008A (zh) 取代的杂芳基双环化合物作为usp1抑制剂及其应用
US20250361239A1 (en) Protein degraders and uses thereof
CN118574825A (zh) 作为fak抑制剂的化合物及其用途
WO2004054504A2 (en) Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US20040127511A1 (en) Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
TW202330544A (zh) 一種調控１５－ｐｇｄｈ活性的化合物、包含其的藥物組合物及其用途
HK1175174A (en) 5-alkynyl pyrimidines and their use as kinase inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM